<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">734589</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2021.734589</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Tanyu Tongzhi Formula Delays Atherosclerotic Plaque Progression by Promoting Alternative Macrophage Activation <italic>via</italic> PPAR&#x3b3; and AKT/ERK Signal Pathway in ApoE Knock-Out Mice</article-title>
<alt-title alt-title-type="left-running-head">Ma et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">TTF Ameliorates Atherosclerosis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Lan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1287487/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dai</surname>
<given-names>Xiaoce</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1096333/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Chenxia</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Mingshuang</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1480930/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Sheng</surname>
<given-names>Hongzhuan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mao</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1400855/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Department of Cardiology, Affiliated Hospital of Nantong University, <addr-line>Nantong</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>The First School of Clinical Medicine of Zhejiang Chinese Medical University, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<label>
<sup>3</sup>
</label>Department of Cardiology, First Affiliated Hospital of Jiaxing University, <addr-line>Jiaxing</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<label>
<sup>4</sup>
</label>Department of Cardiology, First Affiliated Hospital of Zhejiang Chinese Medical University, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff5">
<label>
<sup>5</sup>
</label>Key Laboratory of Integrative Chinese and Western Medicine for the Diagnosis and Treatment of Circulatory Diseases of Zhejiang Province, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/466345/overview">William Chi-Shing Tai</ext-link>, Hong Kong Polytechnic University, Hong Kong SAR, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Wei Mao, <email>maoweilw@163.com</email>; Hongzhuan Sheng, <email>yjshz@ntu.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this&#x20;work</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1439313/overview">Weihong Liu</ext-link>, Capital Medical University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/180530/overview">Andrew Newby</ext-link>, University of Bristol, United&#x20;Kingdom</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/874395/overview">Lei Zheng</ext-link>, Southern Medical University, China</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>734589</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>07</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>11</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Ma, Dai, Wu, Li, Sheng and Mao.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Ma, Dai, Wu, Li, Sheng and Mao</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>We previously demonstrated that the Tanyu Tongzhi Formula (TTF) significantly alleviated the clinical symptoms of patients with coronary heart disease and lowered serum lipid and inflammatory factor levels in patients with coronary heart disease and atherosclerosis model rats. However, the mechanism underlying TTF remains unknown. In this study, we examined the effect of TTF on atherosclerotic plaques in ApoE<sup>-/-</sup> mice and underlying mechanisms involved in macrophage polarization. Sixty male ApoE<sup>-/-</sup> mice were randomly divided into four groups. Mice in the control group were fed a regular diet, whereas experimental mice were fed a high-fat diet and received either saline (HFD group) or TTF at concentrations of 0.60 (TTF-L group) or 2.25&#xa0;g/ml (TTF-H group) by daily oral gavage for 16 weeks. In the TTF-L and TTF-H groups, the levels of serum cholesterol, triglyceride, interleukin (IL)-1&#x3b2;, IL-6, and tumor necrosis factor (TNF)-&#x3b1; were decreased, lipid content was significantly decreased, and percentage area of collagen/lipid increased in atherosclerotic plaque compared to in the HFD group. Moreover, we found TTF promoted the expression of alternative macrophage markers (Fizz1, Arg1, and Mrc) and suppressed the expression of M1 macrophage markers (TNF-&#x3b1;, IL-1&#x3b2;, and IL-6) by regulating peroxisome proliferator-activated receptor &#x3b3; (PPAR&#x3b3;) expression and AKT/extracellular signal-regulated kinase (ERK) activation. We further investigated whether alternative macrophage was reduced when PPAR&#x3b3; was inhibited or the AKT/ERK signaling pathway was activated. TTF delayed atherosclerotic plaque progression by promoting alternative macrophage activation through increasing PPAR&#x3b3; expression and inhibiting AKT/ERK phosphorylation, providing a theoretical basis for its clinical application.</p>
</abstract>
<kwd-group>
<kwd>Tanyu Tongzhi formula</kwd>
<kwd>atherosclerosis</kwd>
<kwd>traditional Chinese medicine</kwd>
<kwd>alternative macrophage activation</kwd>
<kwd>PPAR&#x3b3;</kwd>
</kwd-group>
<contract-num rid="cn001">81973579</contract-num>
<contract-num rid="cn002">JCZ20196</contract-num>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Science and Technology Project of Nantong City<named-content content-type="fundref-id">10.13039/501100018557</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Globally, the disability and fatality rate of cardiovascular diseases, such as coronary heart disease (CHD) and stroke rank first among non-communicable diseases, leading to large medical and economic burdens on society and individuals. Atherosclerosis (AS), the critical pathological basis of these diseases, is a chronic inflammatory disease characterized by narrowing of the blood vessels. The occurrence and development of AS are characterized by accumulation of various immune cells, release of different inflammatory factors, and formation of lipid and necrotic cores. Continued cell influx and proliferation lead to the more advanced lesions (<xref ref-type="bibr" rid="B30">Ross, 1993</xref>). Macrophage aggregation in the endothelium is a key indication of AS (<xref ref-type="bibr" rid="B34">Vergallo and Crea, 2020</xref>). Stimulation of different inflammatory factors in the microenvironment of the lesion induces macrophage polarization. When the number of inflammatory M1 macrophages increases and anti-inflammatory alternative macrophages decrease, the lesion progresses. In contrast, the plaque tends to be stable (<xref ref-type="bibr" rid="B31">Ross et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B32">Tabas and Bornfeldt, 2016</xref>). Macrophage polarization and inflammation, lipid metabolism, cell proliferation, and differentiation-related signaling pathways have been widely examined in the context of AS (<xref ref-type="bibr" rid="B25">Murray, 2017</xref>; <xref ref-type="bibr" rid="B14">Lin et&#x20;al., 2018</xref>).</p>
<p>The treatment of phlegm and blood stasis has a long history in the clinical practice of traditional Chinese medicine for CHD. A large number of clinical and basic research findings have shown that the treatment could effectively improve clinical symptoms, inhibit plaque progression, reduce inflammatory response and protect cardiovascular system in CHD patients and AS animal models (<xref ref-type="bibr" rid="B36">Xie et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B39">Zhe et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B16">Liu et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B29">Ren et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B10">Deng et&#x20;al., 2021</xref>). Our research team has carried out clinical and basic research on the treatment of phlegm and blood stasis and the efficacy indicators mainly include angina pectoris, ECG changes, lipid levels, insulin resistance, inflammatory indicators (Hua et&#x20;al., 2008; <xref ref-type="bibr" rid="B18">Liu et&#x20;al., 2008a</xref>; <xref ref-type="bibr" rid="B17">Liu et&#x20;al., 2008b</xref>; <xref ref-type="bibr" rid="B22">Miao et&#x20;al., 2020a</xref>; <xref ref-type="bibr" rid="B21">Miao et&#x20;al., 2020b</xref>). The Tanyu Tongzhi Formula (TTF) is a prescription based on the fundamental principle of treating phlegm and blood stasis simultaneously, produced in the first affiliated hospital of zhejiang chinese medical university and is derived from &#x201c;Gualou xiebai Banxia Decotion&#x201d; from the classic Chinese medicine &#x201c;<italic>Golden Chamber Yao lve</italic>&#x201d;; the latter formula has been adjusted for use in clinical practice for more than one thousand years (<xref ref-type="bibr" rid="B38">Zhang, 2016</xref>). TTF follows the compatibility principle of &#x201c;monarch, minister, assistant and guide&#x201d; and its effects at the cellular level have been demonstrated previously (<xref ref-type="bibr" rid="B19">Ma et&#x20;al., 2019</xref>). The anti-inflammatory effect can be enhanced by combined administration with other drugs, reducing the cytotoxic effects of drugs. Previous studies confirmed the effectiveness of TTF on CHD in long-term clinical practice and relevant basic research (<xref ref-type="bibr" rid="B17">Liu et&#x20;al., 2008b</xref>; <xref ref-type="bibr" rid="B9">Dai et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B12">Jiang et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B5">Cai et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B4">Cai H. et&#x20;al., 2020</xref>). Additionally, TTF increased the protein expression of peroxisome proliferator-activated receptor &#x3b3; (PPAR&#x3b3;), which participates in regulating alternative macrophage activation in the monocytes of patients with CHD (<xref ref-type="bibr" rid="B17">Liu et&#x20;al., 2008b</xref>; <xref ref-type="bibr" rid="B9">Dai et&#x20;al., 2010</xref>). In this study, we explored whether TTF can alleviate the progression of atherosclerotic plaques and its underlying mechanism in regulating macrophage polarization.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>TTF Preparation</title>
<p>The aqueous extract of TTF was provided by Huisong Co., Ltd. (Hangzhou, China). TTF contains 15&#xa0;g <italic>Trichosanthes</italic> kirilowii Maxim (Cucurbitaceae; Trichosanthis Fructus), 15&#xa0;g Salvia miltiorrhiza Bunge (Lamiaceae; Salviae miltiorrhizae radix et rhizoma), 10&#xa0;g Allium macrostemon Bunge (Amaryllidaceae; Bulbus Allii Macrostemonis), 5&#xa0;g Leech (Hirudinidae; Hirudo), 10&#xa0;g Acorus gramineus Aiton (Araceae; Acori Tatarinowii Rhizoma), 15&#xa0;g Curcuma aromatica Salisb (Zingiberaceae; Curcumae Radix), 20&#xa0;g Poria cocos [Polyporaceae; Wolfiporia cocos (F.A. Wolf) Ryvarden and Gilb], and 10&#xa0;g Citrus &#xd7; aurantium L (Rutaceae; Citri Reticulatae Pericarpium) (<xref ref-type="table" rid="T1">Table&#x20;1</xref>). All drugs in TTF were authenticated by Director Jinxia Wang and Minxia Zheng of the First Affiliated Hospital of Zhejiang Chinese Medical University (Hangzhou, China). Voucher specimens were deposited at the Herbarium of Zhejiang University. The procedure used was as follows: After soaking all drugs (100&#xa0;g) in 1- L distilled water 2&#x20;times for 30&#x20;min, the mixture was boiled for 1&#xa0;h. After collecting the filtrate, an additional 1- L distilled water was added and boiled for 1 h, and the filtrate obtained twice was mixed and concentrated to 0.6&#xa0;mg/ml and 2.25&#xa0;g/ml, respectively. Hence, crude extracts at low and high concentrations were obtained.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Components of TTF.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Chinese name</th>
<th align="center">Place of origin</th>
<th align="center">Family/Voucher number</th>
<th align="center">Authority</th>
<th align="center">Amount (g)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Quan Gua Lou</td>
<td align="left">Shandong, China</td>
<td align="left">Cucurbitaceae/Y.-J.Jin 1</td>
<td align="left">Pharmacopoeia of China (2015)</td>
<td align="char" char=".">15</td>
</tr>
<tr>
<td align="left">Dan Shen</td>
<td align="left">Anhui, China</td>
<td align="left">Lamiaceae/Y.-J.Jin 2</td>
<td align="left">Pharmacopoeia of China (2015)</td>
<td align="char" char=".">15</td>
</tr>
<tr>
<td align="left">Xie Bai</td>
<td align="left">Shandong, China</td>
<td align="left">Amaryllidaceae/Y.-J.Jin 3</td>
<td align="left">Pharmacopoeia of China (2015)</td>
<td align="char" char=".">10</td>
</tr>
<tr>
<td align="left">Shui Zhi</td>
<td align="left">Shandong, China</td>
<td align="left">Hirudinidae/Y.-J.Jin 4</td>
<td align="left">Pharmacopoeia of China (2010)</td>
<td align="char" char=".">5</td>
</tr>
<tr>
<td align="left">Shi Chang Pu</td>
<td align="left">Shandong, China</td>
<td align="left">Araceae/Y.-J.Jin 5</td>
<td align="left">Pharmacopoeia of China (2005)</td>
<td align="char" char=".">10</td>
</tr>
<tr>
<td align="left">Yu Jin</td>
<td align="left">Zhejiang, China</td>
<td align="left">Zingiberaceae/Y.-J.Jin 6</td>
<td align="left">Pharmacopoeia of China (2015)</td>
<td align="char" char=".">15</td>
</tr>
<tr>
<td align="left">Fu Ling</td>
<td align="left">Zhejiang, China</td>
<td align="left">Polyporaceae/Y.-J.Jin 7</td>
<td align="left">Pharmacopoeia of China (2015)</td>
<td align="char" char=".">20</td>
</tr>
<tr>
<td align="left">Chen Pi</td>
<td align="left">Guangdong, China</td>
<td align="left">Rutaceae/Y.-J.Jin 8</td>
<td align="left">Medicinal Plants in China (WHO, 1997)</td>
<td align="char" char=".">10</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-2">
<title>High-Performance Liquid Chromatography</title>
<p>The aqueous extract of TTF (200&#xa0;&#xb5;L) was added to 1&#xa0;ml of 80% methanol, swirled, and shaken for 1&#xa0;min. High-speed centrifugation was performed at 14,000&#xa0;rpm for 10&#xa0;min, and the supernatant was collected. The supernatant was filtered through a 0.22-&#xb5;m filter membrane. Chromatographic analysis collection and integration of uracil, hypoxanthine, adenosine, lithospermic acid B, lithospermic acid, tanshinone I, and quercetin in TTF were evaluated using Xcilabur4.0 software (Thermo Fisher Scientific, Waltham, MA, United&#x20;States). A QExactive high-resolution mass spectrometer (Thermo Fisher Scientiic) coupled with an UltiMate 3000 RS (Thermo Fisher Scientific) was employed for chemical identification.</p>
<p>Mass spectrometry analysis was performed in both positive and negative modes under the following parameters: scan range, 50.0&#x2013;500.0&#xa0;m/z; ion spray pressure, 3.2&#xa0;kV (positive); capillary temperature, 300&#xb0;C. The chromatographic conditions were as follows: chromatographic column, RP-C18 150&#x20;&#xd7; 2.1 mm, Welch; flow rate, 0.300&#xa0;ml/min; aqueous phase, 0.1% formic acid in aqueous solution (mobile phase A); organic phase, acetonitrile (mobile phase B); needle liquid, methanol; column temperature: 35&#xb0;C; automatic sampler temperature, 10.0&#xb0;C.; chromatographic gradient: 0&#x2013;5&#xa0;min, 2 %B; 5&#x2013;10&#xa0;min, 20 %B; 10&#x2013;15&#xa0;min, 50 %B; 15&#x2013;20&#xa0;min, 80 %B; 20&#x2013;25&#xa0;min, 95 %B; 25&#x2013;30&#xa0;min, 2%&#x20;B.</p>
</sec>
<sec id="s2-3">
<title>Animals</title>
<p>The study was approved by the Animal Ethics Committee of Zhejiang Chinese Medical University. Sixty male ApoE<sup>-/-</sup> mice (6&#x2013;8&#xa0;weeks old, 18&#x2013;22&#xa0;g) in the C57/BL6 background were obtained from the Department of Laboratory Animal Science at Nanjing University. All mice were kept in a temperature-controlled room on a 12-h light/dark cycle with food and water available <italic>ad libitum</italic>. Animal experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978).</p>
<p>All mice were adaptively fed for 1&#xa0;week, after which high-fat diet feeding and TTF intragastric administration were started simultaneously. The mice were randomly divided into four experimental groups (15 mice per group): the control group was fed a common diet and HFD group was fed a high-fat diet (Research Diets, Inc, New Brunswick, NJ, United&#x20;States; Lot: D12108C). The formulation of the high-fat diet is shown in <xref ref-type="sec" rid="s11">Supplementary Table S1</xref>; the TTF-L and TTF-H groups were fed the HFD together with 0.2&#xa0;ml low and high concentrations of TTF daily by oral gavage, respectively. After 16&#xa0;weeks, the mice (n &#x3d; 8&#x2013;10 mice per group) were anesthetized with 1% sodium pentobarbital by intraperitoneal injection, and the hearts, aorta, and blood were harvested. The mice were perfused with normal saline through the heart before harvesting the tissues. Finally, the heart with the entire aorta and other tissues was isolated and stored at &#x2212;80&#xb0;C for subsequent histological evaluation or gene expression analysis.</p>
</sec>
<sec id="s2-4">
<title>Serum Biochemical Analysis</title>
<p>Mice were fasted overnight, and then the retro-orbital sinus blood was collected, allowed to coagulate, and centrifuged at 1,000 &#xd7;<italic>g</italic> (RCF) at room temperature to isolate the serum. The serum was immediately frozen and stored at &#x2212;80&#xb0;C. The serum lipid profile, including cholesterol (CHOL), triglycerides (TG), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol (HDL-C), was measured at the Zhejiang Chinese Medical University with an AU 400 fully automated chemistry analyzer (Olympus, Tokyo, Japan) using the enzymatic-colorimetric method. Serum tumor necrosis factor (TNF)-&#x3b1;, interleukin (IL)-6, and IL-1&#x3b2; levels were evaluated by enzyme-linked immunosorbent assay according to the manufacturer&#x2019;s instructions.</p>
</sec>
<sec id="s2-5">
<title>Histological Evaluation of Atherosclerotic Lesions</title>
<p>The en face pinned aortas were stained with Oil-Red-O. Images of the aortas were captured using a stereoscope (Nikon, Tokyo, Japan). The proximal aortas attached to the heart were embedded in OCT compound and frozen at &#x2212;80&#xb0;C. The aortic root was serially sectioned into 7-&#x3bc;m sections from the site where the aortic valve appeared. A set of three consecutive sections was stained with Oil-Red-O and Masson&#x2019;s trichrome for morphological analysis of atherosclerotic plaques. Macrophages and the expression of Arg1 in the aortic root were detected by immunofluorescence staining of sequential sections with rat anti&#x2013;monocyte macrophage (CD68) monoclonal antibody (1&#xa0;&#x3bc;g/ml, abcam, ab237968) and rabbit polyclonal anti-Arg1 (1:1,000, CST, 93668S) at 4&#xb0;C overnight, followed by the corresponding secondary antibodies conjugated with Alexa Fluor&#xae; 488 and 647 (1:5,000, abcam, ab201844 and 1:5,000, CST, 43279S) for fluorescence detection. Images were captured using a Nikon A1R digital camera (Nikon). The sections were quantitatively analyzed using Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, MD, United&#x20;States).</p>
</sec>
<sec id="s2-6">
<title>Cell Culture</title>
<p>Primary peritoneal macrophages (PMs) were isolated from successful modeling ApoE<sup>-/-</sup> mice in the control, HFD, TTF-L, and TTF-H groups. Briefly, the mice&#x20;were</p>
<p>Sacrificed by cervical dislocation, 4&#xa0;ml of ice-cold RPMI medium was injected into the peritoneal cavity, the peritoneum was gently massaged for 1&#x20;min, the RPMI medium was collected and centrifuged at 800&#x20;&#xd7;<italic>g</italic> (RCF) for 5&#xa0;min, and the PMs settled at the bottom of the test tube. The PMs were resuspended and cultured at 5% CO<sub>2</sub> and 37&#xb0;C for 2&#xa0;h in RPMI containing 10% fetal bovine serum, nonadherent cells were removed, and the cells were cultured for subsequent assays.</p>
</sec>
<sec id="s2-7">
<title>CCK-8 Assay</title>
<p>Ten microliters RPMI were added to each well of a 96-well plate, and then 90&#xa0;&#x3bc;L&#xa0;PMs were seeded into the plates at a density of 5&#x20;&#xd7; 10<sup>4</sup> cells/well. After culturing for 2&#xa0;h, nonadherent cells were removed and 90&#xa0;&#x3bc;L RPMI containing TTF was added at gradient of concentrations for 24&#xa0;h. Next, 10&#xa0;&#x3bc;L CCK-8 reagent was added. The cells were placed in an incubator in the dark for 2&#xa0;h. The optical density of the medium was measured using a microplate reader at a wavelength of 450&#xa0;nm.</p>
</sec>
<sec id="s2-8">
<title>Quantitative Real-Time Polymerase Chain Reaction</title>
<p>PMs isolated from ApoE<sup>-/-</sup> mice were incubated with 0.5&#xa0;mg/ml TTF for 6&#xa0;h at 37&#xb0;C and then incubated with 80&#xa0;&#x3bc;g/ml oxidized LDL (ox-LDL; Yiyuan Biotechnologies, Guangzhou, China) for 24&#xa0;h at 37&#xb0;C. Total RNA was isolated from PM cells using TRIzol reagent (Invitrogen, Carlsbad, CA, United&#x20;States). Total RNA (2&#xa0;&#x3bc;g) was reverse-transcribed to cDNA using M-MLV transcriptase (Thermo Fisher Scientific) according to the manufacturer&#x2019;s instructions. Real-time polymerase chain reaction was performed on an ABI 7500 System cycler (Applied Biosystems, Foster City, CA, United&#x20;States) using SYBR Green PCR Master Mix (Transgen Biotic). The expression of six genes (Fizz1, Arg1, Mrc, TNF-&#x3b1;, IL-1&#x3b2;, and IL-6) was normalized against the expression of 18S rRNA. Data were analyzed using the 2<sup>-&#x394;Ct</sup> method. The primers used are shown in <xref ref-type="table" rid="T2">Table&#x20;2</xref>.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>
<bold>&#x7c;</bold> List of primers for quantitative Real-Time PCR.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th colspan="2" align="left">Gene</th>
<th align="center">Oligonucleotide sequence</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="2" align="left">Fizz1</td>
<td align="left">Forward</td>
<td align="left">TAC TTG CAA CTG CCTGTG CTT ACT</td>
</tr>
<tr>
<td align="left">Reverse</td>
<td align="left">TAT CAA AGC TGG GTT CTC CACCTC</td>
</tr>
<tr>
<td rowspan="2" align="left">Arg1</td>
<td align="left">Forward</td>
<td align="left">CTCCAA GCC AAA GTC CTT AGA G</td>
</tr>
<tr>
<td align="left">Reverse</td>
<td align="left">AGG AGC TGTCAT TAG GGA CAT C</td>
</tr>
<tr>
<td rowspan="2" align="left">Mrc</td>
<td align="left">Forward</td>
<td align="left">CAT GAG GCT TCT CCT GCT TCT</td>
</tr>
<tr>
<td align="left">Reverse</td>
<td align="left">TTGCCG TCT GAA CTG AGA TGG</td>
</tr>
<tr>
<td rowspan="2" align="left">TNF-&#x3b1;</td>
<td align="left">Forward</td>
<td align="left">CCC&#x200b;TCA&#x200b;CAC&#x200b;TCA&#x200b;GAT&#x200b;CAT&#x200b;CTT&#x200b;CT</td>
</tr>
<tr>
<td align="left">Reverse</td>
<td align="left">GCT&#x200b;ACG&#x200b;ACG&#x200b;TGG&#x200b;GCT&#x200b;ACA&#x200b;G</td>
</tr>
<tr>
<td rowspan="2" align="left">IL-1&#x3b2;</td>
<td align="left">Forward</td>
<td align="left">GCA&#x200b;ACT&#x200b;GTT&#x200b;CCT&#x200b;GAA&#x200b;CTC&#x200b;AAC&#x200b;T</td>
</tr>
<tr>
<td align="left">Reverse</td>
<td align="left">ATC&#x200b;TTT&#x200b;TGG&#x200b;GGT&#x200b;CCG&#x200b;TCA&#x200b;ACT</td>
</tr>
<tr>
<td rowspan="2" align="left">IL-6</td>
<td align="left">Forward</td>
<td align="left">TTA&#x200b;GTC&#x200b;CTT&#x200b;CCT&#x200b;ACC&#x200b;CCA&#x200b;ATT&#x200b;TCC</td>
</tr>
<tr>
<td align="left">Reverse</td>
<td align="left">TTG&#x200b;GTC&#x200b;CTT&#x200b;AGC&#x200b;CAC&#x200b;TCC&#x200b;TTC</td>
</tr>
<tr>
<td rowspan="2" align="left">18S rRNA</td>
<td align="left">Forward</td>
<td align="left">GCA&#x200b;ATT&#x200b;ATT&#x200b;CCC&#x200b;CAT&#x200b;GAA&#x200b;CG</td>
</tr>
<tr>
<td align="left">Reverse</td>
<td align="left">GGG&#x200b;ACT&#x200b;TAA&#x200b;TCA&#x200b;ACG&#x200b;CAA&#x200b;GC</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-9">
<title>RNA-Sequencing and Gene Expression Analysis</title>
<p>PMs isolated from ApoE<sup>-/-</sup> mice were incubated with 0.5&#xa0;mg/ml TTF for 6&#xa0;h at 37&#xb0;C and then incubated with 80&#xa0;&#x3bc;g/ml oxidized LDL (ox-LDL; Yiyuan Biotechnologies, Guangzhou, China) for 24&#xa0;h at 37&#xb0;C. The RNA-seq library was prepared for sequencing using standard Illumina protocols. Total RNA samples from ApoE<sup>-/-</sup> PMs were isolated using TRIzol reagent. Library construction and sequencing were performed using BGI (Shenzhen, China). For data analysis, base calling was performed using SOAPnuke (v1.5.2). Clean reads were aligned to the genome using HISAT2 v2.0.5. Differential expression was determined using RSEM (v1.2.8), and the significance of differential gene expression was defined by DEGseq according to the combination of the absolute value of log2-fold-change &#x2265; 2 and <italic>p</italic> value &#x2264;0.001. Gene Ontology and pathway annotation and enrichment analyses were based on the GO database (<ext-link ext-link-type="uri" xlink:href="http://www.geneontology.org/">http://www.geneontology.org/</ext-link>) and Kyoto Encyclopedia of Genes and Genomes pathway database (<ext-link ext-link-type="uri" xlink:href="http://www.genome.jp/kegg/">http://www.genome.jp/kegg/</ext-link>), respectively. The R package heatmap was used for hierarchical cluster analysis of gene expression patterns.</p>
</sec>
<sec id="s2-10">
<title>Western Blotting</title>
<p>Equal amounts of cells were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and western blotting analysis was performed using the mouse anti&#x2013;CD68 antibody (1:1,000, abcam, ab955), rabbit anti-Arg1 antibody (1:1,000, CST, 93668S), rabbit anti-TNF-&#x3b1; antibody (1:1,000, CST, 3707S), mouse anti-PPAR&#x3b3; antibody (1:1,000, CST, 95128S), rabbit anti-extracellular signal-regulated kinase (ERK) antibody (1:2000, CST, 4370S), rabbit anti-phosphorylated (p)-ERK antibody (1:1,000, CST, 4695S), rabbit anti-AKT antibody (1:1,000,CST, 4685S), rabbit anti-p-AKT antibody (1:1,000, CST,4060S), and rabbit anti-&#x3b2;-actin antibody (1:2000, diagbio, db10001). Quantification of the band intensity was performed using ImageJ software 1.49v (NIH, Bethesda, MD, United&#x20;States), and the values were normalized to the levels of &#x3b2;-actin.</p>
</sec>
<sec id="s2-11">
<title>Statistical Analysis</title>
<p>Statistical analyses were performed using SPSS version 27.0 software (SPSS, Inc, Chicago, IL, United&#x20;States). All results are presented as the mean&#x20;&#xb1; standard error of the mean. Statistical significance was determined by <italic>t</italic>-test or one-way analysis of variance for data with a normal distribution and by Kruskal&#x2013;Wallis test for non-normally distributed data or small samples. Statistical significance was set at <italic>p</italic>&#x20;&#x3c; 0.05. All cell experiments were performed at least 3&#x20;times.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Quality Control of TTF</title>
<p>Seven chemical compositions were identified in TTF using high-performance liquid chromatography: hypoxanthine (observed m/z: 110.035, retention time (RT): 1.51), uracil (observed m/z: 113.034, RT: 1.57); adenosine (observed m/z: 268.104, RT: 7.33); quercetin (observed m/z: 153.018, RT: 10.13), lithospermic acid B (observed m/z: 719.160, RT: 13.59), lithospermic acid (observed m/z: 539.119, RT: 16.68); and tanshinone I (observed m/z: 279.099, RT: 17.73) (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>). Our results showed that the quality of TTF met the pharmacopeia requirements, which provided a reliable and controllable sample for subsequent experiments.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>HPLC of TTF. <bold>(A)</bold> Seven chemical compositions in TTF were identified by HPLC. <bold>(B)</bold> Chemical structure of (a) hypoxanthine, (b) uracil, (c) adenosine, (d) quercetin, (e) lithospermic acid B, (f) lithospermic acid, (g) tanshinone I.</p>
</caption>
<graphic xlink:href="fphar-12-734589-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Effects of TTF on Plasma Lipid Profiles and Inflammatory Factors in ApoE<sup>-/-</sup> Mice</title>
<p>To investigate the role of TTF in atherosclerotic development, we established an AS model with ApoE<sup>-/-</sup> mice fed a HFD for 16 weeks. Our experimental animal scheme is shown in <xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>. The body weight of mice in the TTF-H group was decreased compared with the control group and HFD group from the 8th week of modeling (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>). The serum lipid levels of mice in the four groups were measured; CHOL and TG levels in the HFD group were significantly higher than those in the control group (<italic>p</italic>&#x20;&#x3c; 0.001, <italic>p</italic>&#x20;&#x3c; 0.01). In the TTF-L group, the CHOL and TG levels piwere decreased compared to that in the HFD group, but the difference was not significant. However, the CHOL and TG levels in the TTF-H group were significantly lower than those in the HFD group (<italic>p</italic>&#x20;&#x3c; 0.01) (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>). The four groups showed no significant difference in LDL-C and HDL-C levels (all <italic>p</italic>&#x20;&#x3e; 0.1). Serum IL-6 and TNF-&#x3b1; levels were significantly higher in the HFD group than in the control group (<italic>p</italic>&#x20;&#x3c; 0.01). The levels of IL-1&#x3b2;, IL-6, and TNF-&#x3b1; in the TTF-H group were much lower than those in the HFD group (<italic>p</italic>&#x20;&#x3c; 0.01) (<xref ref-type="fig" rid="F2">Figures 2D&#x2013;F</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>TTF affects body weight and serum lipid level in ApoE<sup>-/-</sup> mice <bold>(A)</bold> Experimental protocol of the <italic>in vivo</italic> study <bold>(B)</bold> Curve of body weight of ApoE<sup>-/-</sup> mice. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05 vs Control group <bold>(C)</bold> Histogram of serum content of cholesterol, triglyceride, high density lipoprotein and low-density lipoprotein of ApoE<sup>-/-</sup> mice <bold>(D)</bold> Histogram of serum content of IL-1&#x3b2; <bold>(E)</bold> IL-6, and <bold>(F)</bold>TNF-&#x3b1; in ApoE<sup>-/-</sup> mice. Values are presented as means&#x20;&#xb1; SEM (n &#x3d; 10 per group). &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05 vs Control group, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01 vs Control group, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001 vs Control group, &#x23;&#x23;<italic>p</italic>&#x20;&#x3c; 0.01 vs HFD group.</p>
</caption>
<graphic xlink:href="fphar-12-734589-g002.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Effects of TTF on Atherosclerotic Plaque Composition in ApoE<sup>-/-</sup> Mice</title>
<p>We assessed the plaque area and stability using Oil Red O and Masson&#x2019;s trichrome staining. The vivisection of the aortic arch, brachiocephalic trunk, left common carotid artery, and left subclavian artery showed that the HFD significantly increased plaque area in ApoE<sup>-/-</sup> mice, whereas TTF significantly decreased the plaque area in these mice (<xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>). Oil Red O staining of the en face aorta showed that the plaque area in the HFD group was significantly higher than that in the control group (<italic>p</italic>&#x20;&#x3c; 0.01). The plaque areas in the TTF-L and TTF-H groups were also higher than those in the control group (<italic>p</italic>&#x20;&#x3c; 0.01, <italic>p</italic>&#x20;&#x3c; 0.05); however, compared with the HFD group, they were significantly decreased (<italic>p</italic>&#x20;&#x3c; 0.05, <italic>p</italic>&#x20;&#x3c; 0.01) (<xref ref-type="fig" rid="F3">Figures 3B,C</xref>). The results of Oil Red O staining of the aortic valve were consistent with those of the en face (<xref ref-type="fig" rid="F4">Figures 4A,B</xref>). Masson&#x2019;s trichrome staining was used to detect collagen deposition in the plaque region of the aortic valve. The collagen positive areas in the HFD, TTF-L, and TTF-H groups were significantly higher than that in the control group (<italic>p</italic>&#x20;&#x3c; 0.01, <italic>p</italic>&#x20;&#x3c; 0.05, <italic>p</italic>&#x20;&#x3c; 0.05), but they were slightly decreased in the TTF-L and TTF-H groups compared with the HFD group with no significant difference (<xref ref-type="fig" rid="F4">Figures 4C,D</xref>). The staining results suggest that TTF can significantly reduce the lipids and slightly reduce the collagen content in atherosclerotic plaque, which is helpful to delay the progression of plaque (<xref ref-type="bibr" rid="B28">Rekhter, 1999</xref>; <xref ref-type="bibr" rid="B1">Baardman, et&#x20;al., 2020</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>TTF relieves atherosclerotic plaque in ApoE<sup>-/-</sup> mice <bold>(A)</bold> Representative <italic>in vivo</italic> images of aortic arch of ApoE<sup>-/-</sup> mice. The arrows point the location of the AS plaque <bold>(B)</bold> The oil-red-O staining of en face aorta and <bold>(C)</bold> the quantitative analysis of atherosclerotic lesion area of whole aorta. Values are presented as means&#x20;&#xb1; SEM (n &#x3d; 6 per group). &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05 vs Control group, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01 vs Control group, &#x23;<italic>p</italic>&#x20;&#x3c; 0.05 vs HFD group, &#x23;&#x23;<italic>p</italic>&#x20;&#x3c; 0.01 vs HFD&#x20;group.</p>
</caption>
<graphic xlink:href="fphar-12-734589-g003.tif"/>
</fig>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>TTF reduces lipid content and increases collagen content in atherosclerotic plaque of ApoE<sup>-/-</sup> mice. Representative images of <bold>(A)</bold> Oil-Red-O staining and <bold>(B)</bold> the quantitative analysis of relative ORO positive area. Representative images of <bold>(C)</bold> Masson&#x2019;s Trichrome staining of aortic sinus and <bold>(D)</bold> the quantitative analysis of relative collagen positive area. Values are presented as means&#x20;&#xb1; SEM (n &#x3d; 3 per group). &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05 vs Control group, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01 vs Control group, &#x23;<italic>p</italic>&#x20;&#x3c; 0.05 vs HFD group, &#x23;&#x23;<italic>p</italic>&#x20;&#x3c; 0.01 vs HFD group. Bar &#x3d; 50&#xa0;&#x3bc;m.</p>
</caption>
<graphic xlink:href="fphar-12-734589-g004.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>Effects of TTF on Regulating Alternative Macrophage Activation in the Atherosclerotic Plaque</title>
<p>To investigate whether TTF regulated alternative macrophage activation in the atherosclerotic plaques of ApoE<sup>-/-</sup> mice fed a HFD, we conducted immunofluorescence staining and analysis of Arg1 on aortic valve sections. Expression of the total macrophage marker CD68 in the HFD group was significantly higher, whereas expression of the alternative macrophage marker Arg1 was lower than that in the control group. In addition, compared with the HFD group, expression of CD68 in the TTF-L and TTF-H groups significantly decreased, and expression of Arg1 was increased (<xref ref-type="fig" rid="F5">Figure&#x20;5A</xref>). The quantitative analysis of relative Arg1/CD68 positive area showed that the proportion of Arg1 positive macrophages in HFD group was significantly less than that in control group, while the proportion of arg1 positive macrophages in TTF-L and TTF-H groups were significantly higher than that in HFD group (<xref ref-type="fig" rid="F5">Figure&#x20;5B</xref>). Moreover, to detect the expression levels of Macrophage markers in the peritoneal macrophages of ApoE<sup>-/-</sup> mice by quantitative PCR assay, we determined the optimal drug concentration using the CCK-8 assay. The results showed that TTF (0.5&#xa0;mg/ml) was an appropriate dosage for PMs (<xref ref-type="fig" rid="F6">Figures 6A,B</xref>). Furthermore, quantitative PCR showed that TTF promoted mRNA expression of the alternative macrophage markers Fizz1, Arg1, and Mrc and decreased expression of the M1 macrophage markers TNF-&#x3b1;, IL-1&#x3b2;, and IL-6 following stimulation with ox-LDL (<xref ref-type="fig" rid="F6">Figures 6C&#x2013;H</xref>). Moreover, western blotting revealed significant up-regulation of the alternative macrophage-associated gene (Arg1) and down-regulation of the M1&#x20;macrophage-associated gene (TNF-&#x3b1;) in PMs treated with 0.25 and 0.5&#xa0;mg/ml TTF (<xref ref-type="fig" rid="F6">Figure&#x20;6I</xref>). Analysis of the grayscale image showed that Arg1/CD68 levels were significantly higher than TNF-&#x3b1;/CD68 levels in the TTF-L and TTF-H groups (<xref ref-type="fig" rid="F6">Figure&#x20;6J</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>TTF increases the expression of alternative macrophage in atherosclerotic plaque of ApoE<sup>-/-</sup> mice <bold>(A)</bold> Representative images of immunofluorescence staining of aortic sinus. Bar &#x3d; 50&#xa0;&#x3bc;m. Blue for DAPI, green for CD68 and red for Arg1&#x20;<bold>(B)</bold> the quantitative analysis of relative Arg1/CD68 positive area. Values are presented as means&#x20;&#xb1; SEM (n &#x3d; 3 per group). &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05 vs Control group, &#x23;<italic>p</italic>&#x20;&#x3c; 0.05 vs HFD&#x20;group.</p>
</caption>
<graphic xlink:href="fphar-12-734589-g005.tif"/>
</fig>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>TTF affected the expression of mRNA of M1 and alternative macrophage markers. PM cells isolated from ApoE<sup>-/-</sup> mice were treated with 0.5&#xa0;mg/ml TTF for 24&#xa0;h followed by ox-LDL stimulating for 24&#xa0;h <bold>(A)</bold> The cell survival rate of PM pretreated with TTF and IC50 of PM <bold>(B)</bold>. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05 and &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01 vs Control (TTF &#x3d; 0&#xa0;mg/ml) group <bold>(C&#x2013;E)</bold> The mRNA expression of Fizz1, Arg1 and Mrc of alternative macrophage markers <bold>(F&#x2013;H)</bold> The mRNA expression of TNF&#x3b1;, IL-1&#x3b2; and IL-6 of M1 markers. The relative mRNA level was measured by RT-qPCR analysis. Values are presented as means&#x20;&#xb1; SEM (n &#x3d; 3 per group). NS represents no significant with Control (PBS) group, &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05 vs Control (PBS) group, &#x23;<italic>p</italic>&#x20;&#x3c; 0.05 vs TTF (PBS) group, &#x26;<italic>p</italic>&#x20;&#x3c; 0.05 vs TTF (PBS) group <bold>(I)</bold> Western blotting showed the protein expression of CD68, Arg1, and IL-6 in PM cells treated with PBS, TTF-L (0.25&#xa0;mg/ml), and TTF-L (0.5&#xa0;mg/ml) stimulated with ox-LDL (80&#xa0;&#x3bc;g/ml) <bold>(J)</bold> The quantitative analysis of grey ratio of Arg1/CD68 and TNF&#x3b1;/CD68. Values are presented as means&#x20;&#xb1; SEM (n &#x3d; 3 per group). &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05 vs Ctr &#x2b; group, &#x23;<italic>p</italic>&#x20;&#x3c; 0.05 vs TTF-L&#x20;group.</p>
</caption>
<graphic xlink:href="fphar-12-734589-g006.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>Effects of TTF on RNA Expression of Macrophages in ApoE<sup>-/-</sup> Mice</title>
<p>Based on the results described above, TTF regulates M2 polarization in atherosclerotic plaques, but the underlying mechanism was unclear. To determine the specific effect of TTF on the RNA expression of macrophages and related signaling pathways in ApoE<sup>-/-</sup> mice, we collected PMs from ApoE<sup>-/-</sup> mice pretreated with TTF and stimulated with ox-LDL. RNA was isolated and subjected to RNA sequencing. Twelve samples were tested, with three samples from each group. Principal component analysis revealed overall transcriptomic similarity among the four groups (<xref ref-type="fig" rid="F7">Figure&#x20;7A</xref>). Based on the gene expression levels of each sample, we detected differentially expressed genes between PBS- and TTF-pretreated macrophages induced by ox-LDL using a volcano plot (<xref ref-type="fig" rid="F7">Figure&#x20;7B</xref>). The hierarchical clustering of differentially expressed genes are shown in <xref ref-type="fig" rid="F7">Figure&#x20;7C</xref> and the results of pathway classification are shown in <xref ref-type="fig" rid="F7">Figure&#x20;7D</xref>. Vital genes involved in alternative macrophage activation between TTF &#x2b; ox-LDL group and PBS &#x2b; ox-LDL group are shown as a heatmap (<xref ref-type="fig" rid="F7">Figure&#x20;7E</xref>). Our results indicate that PPAR&#x3b3;, AMPK, and inflammatory mediator-related signaling pathways may play critical roles in the effects of TTF on the RNA expression of macrophages in ApoE<sup>-/-</sup>&#x20;mice.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>RNA-seq of PM in ApoE<sup>-/-</sup> mice <bold>(A)</bold> Principal component analysis showed the overall transcriptomic similarity of the four groups <bold>(B)</bold> Differential expression analysis revealed induced by ox-LDL, TTF treatment in macrophages. Volcano plots show the differentially expressed genes (DEGs; fold change &#x3e;2 or &#x3c; &#x2212;2, false discovery rate adjusted <italic>p</italic> value &#x3c; 0.05) in macrophages (DEGs; fold change &#x3e;2 or &#x3c; &#x2212;2, false discovery rate adjusted <italic>p</italic> value &#x3c; 0.05) in macrophages <bold>(C)</bold> Hierarchical clustering of quantitative genes expression profiling for macrophages of PBS &#x2b; ox-LDL and TTF &#x2b; ox-LDL groups <bold>(D)</bold> KEGG pathway analysis of DEGs between PBS &#x2b; ox-LDL and TTF &#x2b; ox-LDL groups <bold>(E)</bold> Selected genes involved in macrophage polarization between TTF &#x2b; ox-LDL and PBS &#x2b; ox-LDL groups are shown as a heatmap.</p>
</caption>
<graphic xlink:href="fphar-12-734589-g007.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>TTF Promotes Alternative Macrophage Activation Through PPAR&#x3b3;, AKT/ERK Pathway</title>
<p>According to the results of RNA sequencing, to detect the protein expression of key molecules in related signal pathways of TTF affecting macrophage polarization, we performed immunoblotting to determine the protein expression and phosphorylation levels of PPAR&#x3b3;, ERK1/2, and AKT in PMs. We found that 0.5&#xa0;mg/ml TTF did not affect the expression of the tested proteins in PMs without ox-LDL stimulation. However, upon stimulation with 80&#xa0;&#x3bc;g/ml ox-LDL, TTF decreased the phosphorylation levels of AKT and ERK and increased the expression of PPAR&#x3b3; significantly (<xref ref-type="fig" rid="F8">Figures 8A&#x2013;D</xref>). The regulation effect on PPAR&#x3b3; and AKT/ERK was related to the concentration of TTF, as 0.5&#xa0;mg/ml TTF (TTF-H) had a stronger regulatory effect than 0.25&#xa0;mg/ml TTF (TTF-L) (<xref ref-type="fig" rid="F8">Figures 8E&#x2013;H</xref>). This effect was remarkably reversed by an AKT activator (recilisib), ERK activator (pamoic acid disodium, PAD), or PPAR&#x3b3; inhibitor (mifobate). The quantitative PCR results revealed decreased relative mRNA levels of Fizz1, Arg1, and Mrc and increased relative mRNA levels of TNF-&#x3b1;, IL-1&#x3b2;, and IL-6 in PMs pretreated with TTF and 30&#xa0;&#x3bc;M AKT activator (recilisib), 25&#xa0;nM ERK activator (PAD), or 50&#xa0;&#x3bc;M PPAR&#x3b3; inhibitor (mifobate) following stimulation with ox-LDL (<xref ref-type="fig" rid="F9">Figure&#x20;9</xref>).</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>TTF affected atherosclerotic plaque through AKT, ERK and PPAR&#x3b3; signal <bold>(A)</bold> Western blotting showed the protein expression of p-AKT, AKT, PPAR&#x3b3;, p-ERK, and ERK in PM cells treated with PBS and TTF (0.5&#xa0;mg/ml) stimulated with ox-LDL (80&#xa0;&#x3bc;g/ml) <bold>(B&#x2013;D)</bold> The quantitative analysis of grey ratio of p-AKT/AKT, PPAR&#x3b3;/&#x3b2;-actin, and p-ERK/ERK <bold>(E)</bold> Western blotting showed the protein expression of p-AKT, AKT, PPAR&#x3b3;, p-ERK, and ERK in PM cells treated with PBS and TTF (0.25, 0.5&#xa0;mg/ml) stimulated with ox-LDL (80&#xa0;&#x3bc;g/ml) <bold>(F&#x2013;H)</bold> The quantitative analysis of grey ratio of p-AKT/AKT, PPAR&#x3b3;/&#x3b2;-actin, and p-ERK/ERK. Values are presented as means&#x20;&#xb1; SEM (n &#x3d; 3 per group). &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05 vs Ctr-group, &#x23;<italic>p</italic>&#x20;&#x3c; 0.05 vs Ctr &#x2b;&#x20;group.</p>
</caption>
<graphic xlink:href="fphar-12-734589-g008.tif"/>
</fig>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>TTF functions through promoting PPAR&#x3b3; signal expression and inhibiting AKT/ERK pathway. PM cells were pretreated with 30&#xa0;&#x3bc;M AKT activator (Recilisib), 25&#xa0;nM ERK activator (PAD), or 50&#xa0;&#x3bc;M PPAR&#x3b3; inhibitor (Mifobate) for 1&#xa0;h, then treated with 0.5&#xa0;mg/ml TTF and 80&#xa0;&#x3bc;g/ml ox-LDL for 24&#xa0;h. Total RNA was extracted and then relative mRNA level of Fizz1&#x20;<bold>(A)</bold>, Arg1&#x20;<bold>(B)</bold>, Mrc <bold>(C)</bold>, TNF-&#x3b1; <bold>(D)</bold>, IL-1&#x3b2; <bold>(E)</bold>, and IL-6 <bold>(F)</bold> were detected by q-PCR. Values are presented as means&#x20;&#xb1; SEM (n &#x3d; 3 per group). &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05 vs group with ox-LDL only; &#x23;<italic>p</italic>&#x20;&#x3c; 0.05 vs group without ox-LDL and TTF; &#x26;<italic>p</italic>&#x20;&#x3c; 0.05 vs group with ox-LDL and TTF.</p>
</caption>
<graphic xlink:href="fphar-12-734589-g009.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Currently, in terms of modern medicine for the prevention and treatment of stable coronary heart disease, the residual risk of secondary prevention with drugs is high. In addition, the stent implantation is one of the mainstream treatments to cure coronary heart disease. However, after stent implantation, it may still not solve the patient&#x2019;s main complaint and have symptoms such as angina pectoris remained. Therefore, more economical and effective methods to prevent and treat AS and CHD are urgently needed. In our previous studies, TTF not only delayed plaque progression in an animal AS model, but also enhanced plasma PPAR&#x3b3; in patients with CHD. PPAR&#x3b3; is known to be one of the central links of alternative macrophage activation (<xref ref-type="bibr" rid="B26">Olefsky and Glass, 2010</xref>), and macrophage polarization is a critical process in atherosclerosis development and regression (<xref ref-type="bibr" rid="B2">Barrett, 2020</xref>; <xref ref-type="bibr" rid="B3">Bonacina et&#x20;al., 2020</xref>). We found that TTF stabilized AS plaques by inducing alternative macrophage activation via the PPAR&#x3b3; and AKT/ERK pathways.</p>
<p>There is a definite interaction between AKT signaling and alternative macrophage activation, and AKT signaling participates in alternative macrophage-enhanced differentiation of periodontal ligament stem cell cementoblastic differentiation (<xref ref-type="bibr" rid="B13">Li et&#x20;al., 2019</xref>). However, alternative macrophage activation functions by activating the phosphorylation of Akt in multiple sclerosis animal models (<xref ref-type="bibr" rid="B35">Weng et&#x20;al., 2019</xref>). The phagocytic ability of alternative macrophages is improved via the Akt/FoxO1 pathway (<xref ref-type="bibr" rid="B15">Liu et&#x20;al., 2019</xref>). In the tumor microenvironment, ERK signaling is positively correlated with alternative macrophage activation (<xref ref-type="bibr" rid="B24">Mu et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B6">Cai J.&#x20;et&#x20;al., 2020</xref>). Insulin modulates macrophage transition from the classic to the alternative macrophage phenotype by upregulating PPAR&#x3b3; expression and inducing P38-mediated dephosphorylation of PPAR-&#x3b3; (Ser112) (<xref ref-type="bibr" rid="B37">Yu et&#x20;al., 2019</xref>). PPAR&#x3b3; plays an important role in many metabolic diseases but its function remains controversial (<xref ref-type="bibr" rid="B7">Chawla, 2010</xref>). It is highly expressed in adipose tissue and atherosclerotic plaques, where it not only promotes the differentiation and storage of lipids, improves insulin sensitivity, and plays an anti-inflammatory role, but also improves the release of nitric oxide synthase from endothelial cells in atherosclerotic plaques and regulates vascular homeostasis (<xref ref-type="bibr" rid="B23">Mirza et&#x20;al., 2019</xref>). However, PPAR&#x3b3; can mediate the expression of pro-inflammatory transcription factors, which can promote AS. In ruptured carotid plaques, macrophage nuclear receptor corepressors can delay plaque progression by inhibiting PPAR&#x3b3; to enhance CD36 scavenger receptor expression (<xref ref-type="bibr" rid="B27">Oppi et&#x20;al., 2020</xref>). Among TCM, numerous botanical drugs can be used to treat AS. Ginsenoside Rg3, one of the main active components of <italic>Panax ginseng</italic>, has been reported to reverse the classic to the alternative macrophage phenotype through PPAR&#x3b3; signaling in diabetic AS mouse models (<xref ref-type="bibr" rid="B11">Guo et&#x20;al., 2018</xref>). In addition to phagocytosis and polarization of macrophages, there are many regulatory necrosis patterns of macrophages in advanced plaques, which are involved in plaque stability (<xref ref-type="bibr" rid="B20">Martinet et&#x20;al., 2019</xref>). (<xref ref-type="bibr" rid="B33">Tao et&#x20;al., 2020</xref>). Therefore, targeting macrophages is an important strategy for treating atherosclerosis.</p>
<p>We established a production process and quality control standard system for TTF granules and liquid extract in line with Good Manufacturing Practice standards. Moreover, based on previous clinical observation studies and animal comparative medicine studies, we conducted A randomized, controlled, multicenter clinical study on the efficacy and safety of tanyutong capsule in the treatment of stable coronary heart disease (phlegm and blood stasis syndrome) (Key R and D project of Zhejiang Provincial Department of science and technology. grant number: 2020C03119) to verify the efficacy and safety of TTF in the prevention and treatment of CHD. In further studies, we will evaluate the specific mechanism of TTF, which would be helpful for the clinical transformation and application of phlegm and blood stasis theory in TCM, and can provide more medication choices for clinical patients with AS <xref ref-type="bibr" rid="B8">Chen et&#x20;al.,&#x20;2007</xref>.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/">https://www.ncbi.nlm.nih.gov/</ext-link>, SRP326359.</p>
</sec>
<sec id="s6">
<title>Ethics Statements</title>
<p>The animal study was reviewed and approved by the Institutional Animal Care and Use Committee at Zhejiang Chinese Medical University.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>WM designed the experiments, WM and HS overviewed the study; LM and XD conducted the experiments and data organization; CW and ML analyzed the results. LM and WM wrote the manuscript.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This work was supported by the National Natural Science Foundation to WM (grant numbers 81973579); Nantong Municipal Science and Technology Project (grant numbers JCZ20196).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2021.734589/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2021.734589/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<sec id="s12">
<title>Abbreviations</title>
<p>TCM, Traditional Chinese Medicine; TTF, Tanyu Tongzhi Formula; HFD, high-fat diet; CHOL, cholesterol; TG, triglyceride; TNF-&#x3b1;, tumor necrosis factor-&#x3b1;; CHD, coronary heart disease; AS, atherosclerosis; PPAR&#x3b3;, peroxisome proliferator-activated receptor &#x3b3;; GMP, Good Manufacturing Practice.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baardman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Verberk</surname>
<given-names>S. G. S.</given-names>
</name>
<name>
<surname>van der Velden</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gijbels</surname>
<given-names>M. J.&#x20;J.</given-names>
</name>
<name>
<surname>van Roomen</surname>
<given-names>C. P. P. A.</given-names>
</name>
<name>
<surname>SluimerRoomen</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Macrophage ATP Citrate Lyase Deficiency Stabilizes Atherosclerotic Plaques</article-title>. <source>Nat. Commun.</source> <volume>11</volume>, <fpage>6296</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-20141-z</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrett</surname>
<given-names>T. J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Macrophages in Atherosclerosis Regression</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source> <volume>40</volume>, <fpage>20</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.119.312802</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonacina</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Martini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Svecla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nour</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cremonesi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Beretta</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Adoptive Transfer of CX3CR1&#x20;Transduced-T Regulatory Cells Improves Homing to the Atherosclerotic Plaques and Dampens Atherosclerosis Progression</article-title>. <source>Cardiovasc. Res.</source> <volume>15</volume>, <fpage>264</fpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvaa264</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2020a</year>). <article-title>Experimental Study on the Different Effects of Tanyu Tongzhi Recipe Regulating Autophagy on Neovascularization in Myocardial Ischemic Area and Atherosclerotic Plaque</article-title>. <source>J.&#x20;Zhejiang Chin. Univer.</source> <volume>7</volume>, <fpage>652</fpage>&#x2013;<lpage>656</lpage>. <pub-id pub-id-type="doi">10.16466/j.issn1005-5509.2020.07.011</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Effect of Tanyu Tongzhi Recipe on Angiogenesis in Atherosclerosis Plaque Rats by Regulating PPAR&#x3b3;/NF-&#x39a;b Pathways</article-title>. <source>Chin. J.&#x20;Integr. Med.</source> <volume>37</volume>, <fpage>579</fpage>&#x2013;<lpage>583</lpage>. <pub-id pub-id-type="doi">10.7661/j.cjim.20170315</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2020b</year>). <article-title>Extracellular Ubiquitin Promotes Hepatoma Metastasis by Mediating M2 Macrophage Polarization via the Activation of the CXCR4/ERK Signaling Pathway</article-title>. <source>Ann. Transl. Med.</source> <volume>8</volume>, <fpage>929</fpage>. <pub-id pub-id-type="doi">10.21037/atm-20-1054</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chawla</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Control of Macrophage Activation and Function by PPARs</article-title>. <source>Circ. Res.</source> <volume>106</volume>, <fpage>1559</fpage>&#x2013;<lpage>1569</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.216523</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Establishment of Atherosclerosis Rat Model with Coagulation of Phlegm and Blood Stasis Syndrome</article-title>. <source>Mod. Integr, J.&#x20;Tradi. Chin. West. Med.</source> <volume>16</volume>, <fpage>3789</fpage>&#x2013;<lpage>3793</lpage>. <pub-id pub-id-type="doi">10.3969/j.issn.1008-8849.2007.26.010</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Effects of Tanyu Tongzhi Granule on TCM Syndrome and PPAR&#x3b3; of Coronary Heart Disease</article-title>. <source>Chin. J.&#x20;Tradi. Chin. Med. Pharm.</source> <volume>25</volume>, <fpage>1112</fpage>&#x2013;<lpage>1114</lpage>. <ext-link ext-link-type="uri" xlink:href="https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjExMTE2Eg96Z3l5eGIyMDEwMDcwNDcaCGhudjJraTlw">https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjExMTE2Eg96Z3l5eGIyMDEwMDcwNDcaCGhudjJraTlw</ext-link>. </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Professor LI Qinghai&#x27;s Experience in Treatment of Coronary Plaque from Pathogenesis of Qi, Phlegm and Stasis</article-title>. <source>J.&#x20;Tradit. Chin. Med.</source> <volume>62</volume>, <fpage>213</fpage>&#x2013;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.13288/j.11-2166/r.2021.03.007</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Ginsenoside Rg3 Mitigates Atherosclerosis Progression in Diabetic apoE-/- Mice by Skewing Macrophages to the M2 Phenotype</article-title>. <source>Front. Pharmacol.</source> <volume>9</volume>, <fpage>464</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2018.00464</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>The Impact of Removing Both Phlegm and Blood Stasis Granule on TC TG LDL-C and HDL-C in Patients with Coronary Heart Disease</article-title>. <source>Chin. Archiv. Trdit. Chin. Med.</source> <volume>28</volume>, <fpage>153</fpage>&#x2013;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.13193/j.archtcm.2010.01.155.jiangdn.019</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X. T.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>D. Q.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>R. X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L. J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>M2 Macrophages Enhance the Cementoblastic Differentiation of Periodontal Ligament Stem Cells via the Akt and JNK Pathways</article-title>. <source>Stem Cells</source> <volume>37</volume>, <fpage>1567</fpage>&#x2013;<lpage>1580</lpage>. <pub-id pub-id-type="doi">10.1002/stem.3076</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.&#x20;L.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Q. J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>S. Q.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Notch Signaling Modulates Macrophage Polarization and Phagocytosis through Direct Suppression of Signal Regulatory Protein &#x3b1; Expression</article-title>. <source>Front. Immunol.</source> <volume>9</volume>, <fpage>1744</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.01744</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>MSC-secreted TGF-&#x3b2; Regulates Lipopolysaccharide-Stimulated Macrophage M2-like Polarization via the Akt/FoxO1 Pathway</article-title>. <source>Stem Cel Res. Ther.</source> <volume>10</volume>, <fpage>345</fpage>. <pub-id pub-id-type="doi">10.1186/s13287-019-1447-y</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.&#x20;X.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>J.&#x20;X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Protective Effect of Formula of Removing Both Phlegm and Blood Stasis on Myocardial Tissues of Chinese Mini-Swine with Coronary Heart Disease of Phlegm-Stasis Cementation Syndrome</article-title>. <source>Zhongguo Zhong Yao Za Zhi</source> <volume>39</volume>, <fpage>726</fpage>&#x2013;<lpage>731</lpage>. <pub-id pub-id-type="doi">10.4268/cjcmm20140434</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K. G.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2008b</year>). <article-title>Relation of Phlegm-Stasis Syndrome with Insulin Resistance and Monocyte PPAR&#x3b3; mRNA Expression in Patients with Coronary Heart Disease</article-title>. <source>Chin. J.&#x20;Integr. Tradi. West. Med.</source> <volume>28</volume>, <fpage>602</fpage>&#x2013;<lpage>605</lpage>. <pub-id pub-id-type="doi">10.3321/j.issn:1003-5370.2008.07.007</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2008a</year>). <article-title>Study on Relationship between Phlegm Stasis Syndrom Differentiation and Corresponding Inflammatory Markers of Coronary Heart Disease</article-title>. <source>China. J.&#x20;Tradit. Chin. Med. Pharm.</source> <volume>23</volume>, <fpage>1121</fpage>&#x2013;<lpage>1124</lpage>. <ext-link ext-link-type="uri" xlink:href="https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjExMTE2Eg96Z3l5eGIyMDA4MTIwMjUaCDVjenRoanZt">https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjExMTE2Eg96Z3l5eGIyMDA4MTIwMjUaCDVjenRoanZt</ext-link>. </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Compatibility Principle in the Tanyu Tongzhi Formula Revealed by a Cell-Based Analysis</article-title>. <source>J.&#x20;Ethnopharmacol.</source> <volume>231</volume>, <fpage>507</fpage>&#x2013;<lpage>515</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2018.11.043</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinet</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Coornaert</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Puylaert</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>De Meyer</surname>
<given-names>G. R. Y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Macrophage Death as a Pharmacological Target in Atherosclerosis</article-title>. <source>Front. Pharmacol.</source> <volume>10</volume>, <fpage>306</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2019.00306</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020b</year>). <article-title>Effects of Danlou Tablet and Xuefu Zhuyu Granule on Atherosclerotic Plaques in ApoE-Gene Knockout Mice</article-title>. <source>Chin. J.&#x20;Integr. Med.</source> <volume>41</volume>, <fpage>577</fpage>&#x2013;<lpage>582</lpage>. <pub-id pub-id-type="doi">10.7661/j.cjim.20200911.041</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020a</year>). <article-title>Effects of Danlou Tablet on Atherosclerosis in ApoE - Gene Knockout Mice</article-title>. <source>Chin. J.&#x20;Integr. Med.</source> <volume>40</volume>, <fpage>1367</fpage>&#x2013;<lpage>1372</lpage>. <pub-id pub-id-type="doi">10.7661/j.cjim.20200515.096</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirza</surname>
<given-names>A. Z.</given-names>
</name>
<name>
<surname>Althagafi</surname>
<given-names>I. I.</given-names>
</name>
<name>
<surname>Shamshad</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Role of PPAR Receptor in Different Diseases and Their Ligands: Physiological Importance and Clinical Implications</article-title>. <source>Eur. J.&#x20;Med. Chem.</source> <volume>166</volume>, <fpage>502</fpage>&#x2013;<lpage>513</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2019.01.067</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Tumor-derived Lactate Induces M2 Macrophage Polarization via the Activation of the ERK/STAT3 Signaling Pathway in Breast Cancer</article-title>. <source>Cell Cycle</source> <volume>17</volume>, <fpage>428</fpage>&#x2013;<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1080/15384101.2018.1444305</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murray</surname>
<given-names>P. J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Macrophage Polarization</article-title>. <source>Annu. Rev. Physiol.</source> <volume>79</volume>, <fpage>541</fpage>&#x2013;<lpage>566</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-physiol-022516-034339</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olefsky</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Glass</surname>
<given-names>C. K.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Macrophages, Inflammation, and Insulin Resistance</article-title>. <source>Annu. Rev. Physiol.</source> <volume>72</volume>, <fpage>219</fpage>&#x2013;<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-physiol-021909-135846</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oppi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nusser-Stein</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Blyszczuk</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jomard</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marzolla</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Macrophage NCOR1 Protects from Atherosclerosis by Repressing a Pro-atherogenic PPAR&#x3b3; Signature</article-title>. <source>Eur. Heart J.</source> <volume>41</volume>, <fpage>995</fpage>&#x2013;<lpage>1005</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehz667</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rekhter</surname>
<given-names>M. D.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Collagen Synthesis in Atherosclerosis: Too Much and Not Enough</article-title>. <source>Cardiovasc. Res.</source> <volume>41</volume>, <fpage>376</fpage>&#x2013;<lpage>384</lpage>. <pub-id pub-id-type="doi">10.1016/s0008-6363(98)00321-6</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>J.&#x20;X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Effect of Formula of Removing Both Phlegm and Blood Stasis on Inflammatory Reaction in Chinese Mini-Swine with Coronary Atherosclerosis</article-title>. <source>Zhongguo Zhong Yao Za Zhi</source> <volume>39</volume>, <fpage>285</fpage>&#x2013;<lpage>290</lpage>. <pub-id pub-id-type="doi">10.4268/cjcmm20140224</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>The Pathogenesis of Atherosclerosis: a Perspective for the 1990s</article-title>. <source>Nature</source> <volume>362</volume>, <fpage>801</fpage>&#x2013;<lpage>809</lpage>. <pub-id pub-id-type="doi">10.1038/362801a0</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Eikelboom</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Anand</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gerstein</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Association of Cyclooxygenase-2 Genetic Variant with Cardiovascular Disease</article-title>. <source>Eur. Heart J.</source> <volume>35</volume>, <fpage>2242</fpage>&#x2013;<lpage>8a</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehu168</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tabas</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bornfeldt</surname>
<given-names>K. E.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Macrophage Phenotype and Function in Different Stages of Atherosclerosis</article-title>. <source>Circ. Res.</source> <volume>118</volume>, <fpage>653</fpage>&#x2013;<lpage>667</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.306256</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yurdagul</surname>
<given-names>A.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Kong</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Doran</surname>
<given-names>A. C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>siRNA Nanoparticles Targeting CaMKII&#x3b3; in Lesional Macrophages Improve Atherosclerotic Plaque Stability in Mice</article-title>. <source>Sci. Transl. Med.</source> <volume>12</volume>, <fpage>eaay1063</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aay1063</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vergallo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Crea</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Atherosclerotic Plaque Healing</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>383</volume>, <fpage>846</fpage>&#x2013;<lpage>857</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra2000317</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Phenotypic Screening-Based Identification of 3,4-disubstituted Piperidine Derivatives as Macrophage M2 Polarization Modulators: An Opportunity for Treating Multiple Sclerosis</article-title>. <source>J.&#x20;Med. Chem.</source> <volume>62</volume>, <fpage>3268</fpage>&#x2013;<lpage>3285</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01635</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Zhang Boli&#x27;s Experience in Treating Coronary Heart Disease</article-title>. <source>J.&#x20;Tradit. Chin. Med.</source> <volume>52</volume>, <fpage>1539</fpage>&#x2013;<lpage>1541</lpage>. <pub-id pub-id-type="doi">10.13288/j.11-2166/r.2011.18.004</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Insulin Promotes Macrophage Phenotype Transition through PI3K/Akt and PPAR-&#x3b3; Signaling during Diabetic Wound Healing</article-title>. <source>J.&#x20;Cel. Physiol.</source> <volume>234</volume>, <fpage>4217</fpage>&#x2013;<lpage>4231</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.27185</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2016</year>). <source>Synopsis of Prescriptions of the golden Chamber</source>. <publisher-loc>Beijing, China</publisher-loc>: <publisher-name>New World Press</publisher-name>, <fpage>125</fpage>&#x2013;<lpage>121</lpage>. </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhe</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Study on Traditional Chinese Medicine Syndrome Evolution Rules in Patients with Unstable Angina Pectoris during Percutaneous Coronary Intervention. China</article-title>. <source>J.Tradit. Chin. Med. Pharm.</source> <volume>28</volume>, <fpage>627</fpage>&#x2013;<lpage>630</lpage>. </citation>
</ref>
</ref-list>
</back>
</article>